Navigation Links
A scientific breakthrough on the control of the bad cholesterol
Date:11/24/2008

Montral, November 24, 2008 A study performed by the team of Dr. Nabil G. Seidah, Director of the Biochemical Neuroendocrinology Research Unit at the IRCM, shows for the very first time that the degradation by PCSK9 of the LDLR receptor, which is responsible for removing the bad cholesterol (LDL-cholesterol) from the bloodstream, may be inhibited by a third protein, annexin A2. This major discovery co-authored by Gatan Mayer, a postdoctoral fellow, Steve Poirier, a doctoral student, and Dr. Seidah was published on November 14 in the Journal of Biological Chemistry (JBC).

Genetic studies on humans have clearly shown that PCSK9 is a prime therapeutic target for the prevention and treatment of cardiovascular diseases. PCSK9 proprotein convertase promotes the degradation of the receptor responsible for eliminating LDL-cholesterol particles. Thus, the presence of PCSK9 leads to a surplus of bad cholesterol in the bloodstream and contributes to plaque formation, leading to blockage of blood vessels and arteries. This phenomenon is a major risk factor that can lead to cardiovascular diseases, such as heart attack, atherosclerosis and stroke. Mutations of human genes have demonstrated that a rise in PCSK9 activity results in a major increase in LDL-cholesterol and familial hypercholesterolemia. Conversely, in people with a non-functional mutation in the gene coding for PCSK9, a decrease in its activity brings down the LDL-cholesterol concentration levels in the bloodstream and diminishes by up to 88% the risks of developing cardiovascular diseases.

"By performing a series of biochemical experiments, we discovered that annexin A2 binds strongly to PCSK9 and inhibits its function," remarks Gatan Mayer, the article's first author. This discovery should pave the way toward the development of a new drug that would lower blood cholesterol to recommended levels. Currently, cholesterol lowering drugs known as "statins" are used by more than 25 million people worldwide. Statins decrease cholesterol synthesis and increase the number of LDL-receptors, thus efficiently decreasing plasma cholesterol levels; however, they also increase the amount of PCSK9, which degrades those receptors, thus reducing the effect of statins. A drug that would block PCSK9 could either be used alone or jointly with statins and would be highly beneficial to patients in whom statins do not work or are unable to take this drug.


'/>"/>

Contact: Nabil G. Seidah
seidahn@ircm.qc.ca
514-987-5609
Institut de recherches cliniques de Montreal
Source:Eurekalert

Related biology news :

1. Barrow scientists solve 200-year-old scientific debate involving visual illusions
2. Scientific community called upon to resolve debate on net energy once and for all
3. Top scientific meeting urges coordinated response to economic and environmental crises
4. Loggerhead release to provide vital information to scientific community
5. NIAID scientists to speak on range of infectious disease topics at major scientific meeting
6. ETH Zurich-administered fund ends scientific anonymity
7. Gene therapy anti-cancer research featured in Scientific American
8. In scientific first, Einstein researchers correct decline in organ function associated with old age
9. The emerging scientific discipline of aeroecology
10. Significant impact factor boost for scientific journal Genome Research
11. Scientific information largely ignored when forming opinions about stem cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a ... healthy lifestyle, announced today the official launch of its much-anticipated Pono Board: a re-invented ... , In development for over a year, the patented Pono Board is the ...
(Date:1/17/2017)... Belgium (PRWEB) , ... January 17, 2017 , ... ... sample preparation and epigenetics research, recently announced a collaboration with the Heidelberg University ... DNA amplification method for library preparation, following the company’s successful launch of ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of ... on the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) ... and one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman ...
(Date:1/16/2017)... Jan. 16, 2017  Eurofins Genomics today announced the ... more customers to receive their primers in a shorter ... in quality found with other providers. Express oligos are ... at no additional fee. Researchers ... studies, including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. ...
Breaking Biology Technology: